An emerging target for selectively killing CSCs with a PPP-dependent phenotype is the nuclear factor erythroid 2-related factor 2 (NRF2), the master regulator of the antioxidant defense, whose function in cancer biology has been extensively explored. The gene discussed is NFE2L2; the disease is cancer.